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pathology after mild traumatic brain injury
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Abstract
Background: Millions of people experience traumatic brain injury (TBI) as a result of falls, car accidents, sports
injury, and blast. TBI has been associated with the development of neurodegenerative conditions such as
Alzheimer’s disease (AD) and chronic traumatic encephalopathy (CTE). In the initial hours and days, the pathology
of TBI comprises neuronal injury, breakdown of the blood–brain barrier, and inflammation. At the cellular level, the
inflammatory reaction consists of responses by brain-resident microglia, astrocytes, and vascular elements as well
as infiltration of peripheral cells. After TBI, signaling by chemokine (C-C motif) ligand 2 (CCL2) to the chemokine
(C-C motif) receptor 2 (CCR2) is a key regulator of brain infiltration by monocytes.
Methods: We utilized mice with one or both copies of Ccr2 disrupted by red fluorescent protein (RFP, Ccr2RFP/+
and Ccr2RFP/RFP). We subjected these mice to the mild lateral fluid percussion model of TBI and examined several
pathological outcomes 3 days later in order to determine the effects of altered monocyte entry into the brain.
Results: Ccr2 deletion reduced monocyte infiltration, diminished lesion cavity volume, and lessened axonal damage
after mild TBI, but the microglial reaction to the lesion was not affected. We further examined phosphorylation of
the microtubule-associated protein tau, which aggregates in brains of people with TBI, AD, and CTE. Surprisingly,
Ccr2 deletion was associated with increased tau mislocalization to the cell body in the cortex and hippocampus by
tissue staining and increased levels of phosphorylated tau in the hippocampus by Western blot.
Conclusions: Disruption of CCR2 enhanced tau pathology and reduced cavity volume in the context of TBI. The
data reveal a complex role for CCR2+ monocytes in TBI, as monitored by cavity volume, axonal damage, and tau
phosphorylation.
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Background
Traumatic brain injury (TBI) is a common condition in
today’s society. It is variable in extent and circumstance
and imposes enormous suffering and expense. The
injury can be sustained in a single event or in a repeti-
tive fashion, can be either closed head or penetrating,
and ranges in severity from mild to severe. About 75 %
of TBI is closed head in nature and mild in intensity [1].
Further contributing to patient suffering and impact on
society, TBI is linked to the development of neurodegen-
erative conditions. For example, TBI of varying intensity
is associated with increased risk or earlier onset of
Alzheimer’s disease (AD), and repetitive mild TBI is associ-
ated with chronic traumatic encephalopathy (CTE) [2–8].
One common pathological feature of TBI, AD, and
CTE is the hyperphosphorylation and mislocalization of
the microtubule-associated protein tau (MAPT, here
termed tau) [9]. Tau contains numerous potential phos-
phorylation sites and is a target of multiple kinases. In
physiological conditions, tau is phosphorylated at a few
sites and is located in axons where it binds to microtu-
bules to stabilize the axonal cytoskeleton. However, in
pathological conditions, tau can be phosphorylated at
multiple additional sites. The (hyper)phosphorylated tau
(pTau) dissociates from microtubules in the axon, trans-
locates to the cell body and proximal dendrites, and
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aggregates in structures termed neurofibrillary tangles,
leading to impaired axonal function [9]. While the
mechanisms driving tau phosphorylation and tangle
formation are not well established, there is substantial
evidence suggesting that inflammation can promote this
process [10–12].
A prominent feature of TBI is the development of an
inflammatory reaction within minutes of the injury event
[13–17]. Cells at the site of injury secrete cytokines and
chemokines that lead to the recruitment of peripheral
immune cells—initially neutrophils, which are quickly
replaced by monocytes. Concurrently, there is activation
of brain-resident astrocytes and microglia. The inflam-
matory reaction could contribute to the progression of
axonal pathology and tissue damage and is thus a poten-
tial target to ameliorate TBI pathology [13, 17, 18].
Although inflammation increases tau phosphorylation
and pTau is detected in central nervous system (CNS)
tissues of TBI patients and in animal models, whether
post-injury inflammation affects pTau levels in the
context of TBI has not been addressed. Here, we used
the lateral fluid percussion injury (LFPI) model of TBI
[19, 20] to study how modulation of the monocytic
reaction after TBI influences tau phosphorylation. In
the context of TBI, the monocytic population is pri-
marily represented by CD45loCX3CR1hiCCR2− micro-
glia, CD45hiCX3CR1loCCR2hi inflammatory monocytes,
and CD45hiCX3CR1hiCCr2lo patrolling monocytes [21–24],
but perivascular and meningeal macrophages may also
play a role. We employed mice deficient for either chemo-
kine (C-X3-C motif) receptor 1 (Cx3cr1GFP/GFP mice) or
chemokine (C-C motif) receptor 2 (Ccr2RFP/RFP mice).
Ccr2RFP/RFP mice display reduced infiltration of Ly6Chi in-
flammatory monocytes into the brain after TBI [25]. Here,
Cx3cr1GFP/GFP mice showed no difference in TBI path-
ology compared to wild type (WT) mice, but Ccr2RFP/RFP
mice had reduced lesion volume and axonal pathology.
Surprisingly, Ccr2RFP/RFP mice also exhibited increased
levels and mislocalization of pTau in the cortex and
hippocampus, suggesting that monocyte-dependent in-
flammation exerts distinct effects on tissue loss as com-
pared to tau phosphorylation after TBI.
Methods
Animals and TBI induction
All procedures performed on animals were reviewed and
approved by the Institutional Animal Care and Use Com-
mittee of the Cleveland Clinic. We employed two mouse
strains (Cx3cr1GFP/GFP and Ccr2RFP/RFP) that allowed us to
manipulate the cellular reaction after TBI and at the same
time visualize the inflammatory cells of interest [26].
Cx3cr1GFP/GFP mice (green fluorescent protein (GFP) ex-
pression in microglia and patrolling CCR2lo monocytes)
were maintained on the Ccr2RFP/+ background in which
only one copy of Ccr2 is disrupted (red fluorescent protein
(RFP) expression in inflammatory CCR2hi monocytes,
some T cells). Similarly, for some experiments Ccr2RFP/RFP
mice were maintained on the Cx3cr1GFP/+ background.
There were no statistical differences in the responses to TBI
by Ccr2RFP/RFP ; Cx3cr1+/+ and Ccr2RFP/RFP; Cx3cr1GFP/+
mice (data not shown) and the two genotypes were pooled
together for analysis. Microglia were identified by Iba1 stain-
ing in Ccr2RFP/RFP mice at 3 days post injury (dpi), before
other cell types have upregulated Iba1 expression [27].
To induce TBI, we performed lateral fluid percussion
injury as described before [19]. Briefly, 8–10-week-old
male and female mice were anesthetized with 100 mg/kg
ketamine/10 mg/kg xylazine; the fur on top of the head
was shaved, and the skin was cut and moved to the side.
A craniotomy with ~3 mm diameter was opened on the
right side of the central suture, halfway between Bregma
and Lambda, without disturbing the underlying dura
mater. A modified Leur-Lok hub was placed around the
craniotomy and sealed in place with dental acrylic. The
mice were allowed to recover from anesthesia and
returned to their home cages. On the next day, the mice
were anesthetized again and attached to a fluid per-
cussion device (AmScien Instruments FP-302) by the
Leur-Lok hub. The device was calibrated to deliver mild
injury with pressure intensities between 0.4 and 0.6 atm.
After injury, the hub was removed, the skin was sutured,
and mice were returned to their home cages to recover.
For all experiments, the mice were euthanized 3 dpi.
Tissue staining
Tissue staining was used to evaluate the extent of the in-
flammatory reaction after TBI, lesion volume, axonal
pathology, and tau phosphorylation and localization. At
3 dpi, mice were deeply anesthetized with ketamine/
xylazine and perfused with ice-cold phosphate-buffered
saline (PBS) followed by 4 % paraformaldehyde (PFA) in
PBS. The brains were isolated and postfixed in 4 % PFA
overnight and sectioned on a sliding microtome at
30 μm thickness. During staining, all washes were per-
formed three times for 5 min each in 0.1 % triton X-100
in PBS. Antibody solutions were prepared in PBS unless
otherwise noted.
To visualize the inflammatory reaction after TBI, serial
sections spaced 150 μm apart and spanning ~4 mm
thickness around the injury cavity were blocked in
10 % normal goat serum (NGS) and stained overnight
at 4 °C with mouse anti-GFP (UCDavis/NIH Neuro-
Mab Facility #75-132, 1:8000 dilution), or rabbit anti-Iba1
(Wako #019-19741, 1:1000) antibodies to identify micro-
glia, and rabbit or rat anti-RFP (Abcam #ab62341, 1:1000
and Chromotek #5 F8 α-Red, 1:1000, respectively)
antibodies to identify infiltrating monocytes. The secondary
antibodies (Goat anti-mouse-Alexa 488, Invitrogen
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#A11029; anti-Rabbit IgG-Alexa Fluor 488, Invitrogen
#A11008; anti-rabbit-Alexa 594, Invitrogen #A11037; anti-
Rat IgG-Alexa Fluor 594, Invitrogen #A11007, all at
1:1000 dilution) were applied for 1 h at room temperature
(RT). The sections were mounted on large glass slides,
coverslipped and imaged.
Axonal pathology was assessed with amyloid precursor
protein (APP) staining which accumulates in axonal swell-
ings of damaged neurons [28]. The sections were incu-
bated in 0.3 % H2O2 for 30 min at RT to inactivate
endogenous peroxidases. Antigen retrieval was performed
in 1× Target retrieval solution (Dako Cytomation #S1699)
containing 0.5 % Tween in PBS at 95 °C for 10–15 min.
After blocking in 10 % NGS, primary rabbit anti-APP anti-
body (Invitrogen #51-2700) was applied overnight at 4 °C
and secondary biotinylated goat anti-rabbit antibody
(Vector BA-1000) was applied for 1 h at RT. The signal
was detected using the ABC Elite Kit (Vector PK-6100)
and DAB substrate kit (Vector SK-4100) according to the
manufacturer’s instructions. Sections were allowed to dry
and coverslipped with hardset mounting medium (Fisher
Scientific #SP15).
For phosphorylated tau, after antigen retrieval and
blocking in 5 % NGS and 0.3 % Triton X-100 in PBS for
2 h at RT, the localization of pTau was detected with the
mouse anti-AT8 antibody (ThermoSci mn1020, 1:500 di-
lution in 5 % NGS, 0.3 % Triton X-100 in PBS) overnight
at 4 °C. The secondary antibody used, goat anti-mouse-
Alexa 647 (Invitrogen #A21235, 1:1000 dilution), was
chosen not to interfere with the signal of genetically
encoded GFP and RFP and was applied for 1 h at RT. The
sections were mounted on glass slides and coverslipped
with VectaShield with DAPI medium (Vector H-1200).
Imaging and image quantification
Sections stained with GFP (or Iba1) and RFP were im-
aged on a Leica CTR5500 microscope equipped with a
QImaging Retiga EXi FAST 13941 MONO camera at
10× magnification. Tiling of consecutive fields of view
was employed to capture the whole section and all sec-
tions from a mouse using ImagePro Plus software to
drive the microscope. Both GFP/Iba1 (microglia) and
RFP (monocyte) channels were recorded. The resulting
images were then analyzed with ImageJ software (National
Institutes of Health) to calculate (1) lesion cavity volume,
(2) the volume of brain tissue (in 4 mm slab) occupied by
microglial immunoreactivity, and (3) volume of brain tis-
sue occupied by monocyte immunoreactivity. Initially,
each slice was manually outlined; for slices with a TBI-
induced cavity, the “whole slice” outline was generated
based on where the tissue would be if it were not missing.
Then, the cavity, the region around the cavity with
increased GFP/Iba1 immunoreactivity, and the region
around the cavity with increased RFP immunoreactivity
were manually outlined for each brain section. Finally, all
sections (~22) for an animal were multiplied by the
distance between sections (150 μm) and summed up to
obtain the corresponding volumes (cavity, microglia, and
monocyte immunoreactivity) as a percentage of the brain
volume analyzed (4 mm thickness).
APP-stained sections were also imaged with tiling but
in brightfield mode. To quantify axonal damage, the cor-
pus callosum in the ipsilateral side to the injury was
manually outlined in ImageJ and the percentage of the
corpus callosum with APP immunoreactivity above
threshold was calculated. Two sections were stained for
each animal and averaged after quantification.
AT8-stained sections were imaged on a fluorescent
Leica DM4000 microscope equipped with a QImaging
Retiga EXi FAST 1394 MONO camera. Images were ac-
quired at 10–20× magnification with a Cy5 filter cube
(band-pass excitation 620/60 nm, band-pass emission
700/75 nm filters, 660 nm dichroic mirror). The same
fields were also acquired through a DAPI filter cube
(band-pass 360/40 nm excitation, band-pass 470/40
emission, 400 nm dichroic mirror) to localize cell nuclei.
Images were taken of the ipsilateral cortex (close to the
injury cavity), the underlying ipsilateral hippocampus
and the contralateral cortex and hippocampus.
Western blot and pTau quantification
pTau levels after TBI were quantified by Western blot.
TBI and sham mice were anesthetized with ketamine/
xylazine at 3 dpi and perfused with ice-cold PBS. Naïve
mice that did not undergo any surgery were used as a
control for the effect of surgery itself; naïve mice were
simply anesthetized and perfused. The brains were iso-
lated, the ipsilateral and contralateral hemispheres were
separated (right and left for naïve mice), and the cortices
and hippocampi were microdissected from each hemi-
sphere. Tissues were homogenized in Tissue Protein Ex-
traction Reagent (Pierce #78150) containing 1 % each of
protease and phosphatase inhibitors (Sigma #P8340 and
#P5726, respectively).
Fifty nanograms of total protein were separated on 4–
12 % bis-tris gels (Invitrogen #NP0322) and transferred
to 0.45 μm PVDF membranes (Millipore #IPFL10100).
Separate membranes were run for the detection of phos-
phorylated tau (with mouse anti-AT8 antibody, 1:5000
dilution) and total tau (mouse anti-Tau5 antibody,
Invitrogen #ahb0042. 1:5000). After running, the mem-
branes were activated in methanol, blocked, and incu-
bated in primary antibodies overnight at 4 °C. GAPDH
(Trevigen #2275-PC-100, 1:10,000) was used as loading
control on all membranes. Proteins were detected with
goat anti-mouse IRDye 800CW (for AT8 or Tau5, Li-
Cor #926-68171) and goat anti-rabbit IRDye 680RD (for
GAPDH, Li-Cor #827-08364) fluorescent antibodies.
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Images of the developed membranes were acquired on a
Li-Cor Odyssey CLx imager.
To quantify the relative levels of pTau across samples,
the channels for tau and GAPDH were split and ana-
lyzed separately with the ImageJ Gel tool. Both AT8 and
Tau5 signals were first normalized to GAPDH to ensure
equal sample loading. Then, the relative AT8 signal was
normalized to total tau. There were no significant dif-
ferences in total tau between samples after TBI (data not
shown).
Statistical analysis
Data points on the graphs represent individual mice. The
average and standard error of the mean are also shown.
The effects of genotype and injury intensity were exam-
ined by two-way analysis of variance (ANOVA); statistical
differences between groups were determined with Tukey’s
post hoc tests. All significant values in post hoc tests were
adjusted for multiple comparisons. Groups were consid-
ered to be statistically different if p < 0.05 for both factor
effect (in ANOVA) and post hoc tests.
Results
Preventing CCR2+ monocyte infiltration after TBI reduces
lesion pathology
The inflammatory reaction is a common feature of TBI.
Here, we addressed how modulating monocytic inflamma-
tion might affect pathological features of neurodegenera-
tion. We altered the inflammatory reaction in two
different ways: by inactivation of Cx3cr1 (in Cx3cr1GFP/GFP
mice), which affects the activation of brain-resident
microglia [29] and Ly6Clo patrolling monocytes, or by in-
activation of Ccr2 (in Ccr2RFP/RFP mice), which reduces
the infiltration of Ly6Chi inflammatory monocytes and a
subset of T cells into the brain after TBI [25]. Intercrossing
these two mouse strains allowed us to not only inactivate
the genes of interest, but also directly visualize chemokine
(C-X3-C motif) receptor 1 (CX3CR1)- and CCR2-positive
cells in tissue sections [26]. CX3CR1+ patrolling mono-
cytes and CCR2+ T cells represent only a small proportion
of infiltrating cells after TBI compared to CX3CR1+
microglia and CCR2+ inflammatory monocytes, res-
pectively (data not shown). Hence, we herein refer to
GFP-positive cells as microglia and RFP-positive cells as
infiltrating inflammatory monocytes.
Ccr2RFP/RFP, Cx3cr1GFP/GFP, and control double-
heterozygous mice were subjected to mild LFPI, and
the inflammatory reaction and cavity pathology were ana-
lyzed 3 dpi from brain sections spanning a 4-mm portion
of the brain that encompassed the whole lesion area
(Fig. 1). As expected, the injury induced microglial mor-
phological transformation (seen as increased GFP/Iba1
signal) and infiltration of hematogenous monocytes
(presence of RFP+ cells) at the site of damage in control
double-heterozygous Cx3cr1GFP/+; Ccr2RFP/+ mice (Fig. 1a).
The increased GFP signal and presence of RFP+ cells were
mostly restricted to the site of tissue damage and brain
cavitation. Moreover, the GFP+ cells had mainly ramified,
bushy, morphology, suggesting that at this early time
point, these cells were likely activated microglia rather
than infiltrating CX3CR1+ monocytes. Interestingly, al-
though care was taken not to disturb the dura mater and
underlying brain during craniotomy, the “sham” surgery
itself induced a low level of microglial activation and
monocyte infiltration (Fig. 1a). Consistent with previous
studies [23, 30], deletion of Ccr2 prevented the infiltration
of peripheral CCR2-positive cells into the brain after TBI
as evident by the absence of RFP+ cell staining at the in-
jury site (Fig. 1b). However, there was still prominent
microglial reaction as monitored by GFP or Iba1 staining
(Fig. 1b). In contrast, neither microglial activation nor
monocyte infiltration in response to TBI appeared altered
in Cx3cr1GFP/GFP mice at 3 dpi (Fig. 1c).
We quantified the inflammatory reaction and the cav-
ity pathology by calculating the percentage of the brain
parenchyma (in a 4-mm brain portion around the injury)
that was occupied by reactive microglia, infiltrating
monocytes or size of tissue cavity (Fig. 2). Both injury
and genotype had a significant effect on the cavity vol-
ume (Fig. 2a; two-way ANOVA, p < 0.001 for Injury and
p < 0.05 for Genotype) and monocytic reaction (Fig. 2b;
two-way ANOVA, p = 0.0010 for Injury and p < 0.01 for
Genotype), but there was no significant change in the
microglial reaction under any conditions examined
(Fig. 2c; two-way ANOVA, p = 0.0501 for Injury and
p = 0.1116 for Genotype). Consistent with the tissue
staining (Fig. 1), Ccr2 deletion resulted in a significant de-
crease in cavity volume (Fig. 2a; two-way ANOVA and
Tukey’s post hoc test, p < 0.05 compared to heterozygous
control) and portion of the brain parenchyma containing
monocytes (Fig. 2b; two-way ANOVA and Tukey’s post
hoc test, p < 0.05 compared to heterozygous control). Des-
pite this, there was no change in the microglial reaction in
Ccr2RFP/RFP mice (Fig. 2c; two-way ANOVA and Tukey’s
post hoc test, p = 0.9606).
Deletion of Cx3cr1 did not affect the inflammatory re-
action or cavity volume when comparing knockout to
heterozygous mice (Fig. 2a-c; two-way ANOVA and
Tukey’s post hoc test, p = 0.2205 for cavity volume,
p = 0.0781 for monocytic reaction, and p = 0.1463 for
microglial reaction). Because Cx3cr1 deletion did not
affect either the inflammatory reaction or cavity volume
after mild injury here, we continued all subsequent studies
only with Ccr2RFP/RFP mice and appropriate controls.
Ccr2 deletion reduces TBI-induced axonal pathology
After TBI, axonal pathology is characterized by APP-
positive axonal swellings and axonal retraction bulbs
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indicating axotomy at sites remote to the injury [28]. In
the present study, we detected increased APP immuno-
reactivity, especially in the corpus callosum underlying
the injury site at 3 dpi (Fig. 3a). Examining the corpus
callosum at higher magnification showed that many of
the APP-positive structures seemed to align with the
direction of axonal tracts (Fig. 3b). Deletion of Ccr2
appeared to reduce APP immunoreactivity after TBI.
Quantifying axonal pathology as the percentage of the
corpus callosum with APP immunoreactivity confirmed
reduced axonal pathology in Ccr2RFP/RFP mice at 3 dpi
compared to controls (Fig. 3c; two-way ANOVA and
Tukey’s post hoc test, p < 0.05).
Ccr2 deletion alters tau phosphorylation and localization
Because inflammation has been shown to modulate tau
pathology and Ccr2 deletion reduces monocyte-mediated
inflammation after TBI [10–12, 23, 30], we examined the
effect of TBI on tau phosphorylation in Ccr2RFP/RFP mice.
We initially analyzed changes in tau phosphorylation by
Fig. 1 Modulation of the inflammatory reaction at 3 days after LFPI in CCR2 and CX3CR1 transgenic mice. Control Ccr2RFP/+;Cx3cr1GFP/+ (a), Ccr2RFP/RFP
(b), and Cx3cr1GFP/GFP (c) mice were subjected to surgery (craniotomy; Sham mice) or mild injury, and brains were collected 3 days later. Serial sections
were stained for GFP (a, b (Mild), and c) or Iba1 (b (Surgery)) to visualize microglia or RFP to visualize infiltrating bone marrow-derived monocytes
(BMDM). Inflammatory cells are mostly restricted to the site of injury. Scale bar on images with whole slices, 1 cm. The brightness on the images was
adjusted to allow an easier distinction of the brain sections from the background; all sections in a series were adjusted to the same brightness level.
Magnified images show a close up view of microglial and monocyte distribution around the cavity size. Note the reduced number of RFP+ cells in
Ccr2RFP/RFP mice. Scale bar for magnified images, 100 μm
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fluorescent immunohistochemistry to determine the
localization of pTau (Fig. 4). Tissue staining for the AT8
pTau epitope showed increased staining at the site of
injury in the cortex of both control heterozygous and
Ccr2RFP/RFP mice (Fig. 4a). While the pTau immunore-
activity at the lesion site appeared rather diffuse in
heterozygous mice, pTau signal was mostly perinuclear in
Ccr2RFP/RFP mice (Fig. 4c). It should be noted that the
physiological location of tau is in the axon; hence, both in-
creased phosphorylation and mislocalization to the cell
soma after TBI are abnormal.
Increased tau phosphorylation was also detected re-
mote to the injury at 3 dpi, in the underlying hippo-
campus in both control and Ccr2RFP/RFP mice (Fig. 4b).
However, the pattern of pTau immunoreactivity ap-
peared different in the two genotypes. As in the cortex,
AT8 immunoreactivity in the hippocampus of heterozy-
gous Ccr2RFP/+ TBI mice was mostly diffuse and located
in the hilus of the dentate gyrus, outside the granule cell
layer. In contrast, AT8 signal in the hippocampus of
Ccr2RFP/RFP mice was the highest around cell bodies in
the granule cell layer of the dentate gyrus and hilus
(Fig. 4b, c). Thus, TBI increases tau phosphorylation in
both control and Ccr2RFP/RFP mice, but only Ccr2RFP/RFP
mice show clear pTau translocation to the cell soma.
Both injury and Ccr2 genotype affect pTau levels by
Western blot
In order to quantify the changes in pTau after TBI, we
performed Western blot analysis for the AT8 pTau epi-
tope in microdissected cortical or hippocampal lysates.
Because the hub-placement surgery itself influenced the
inflammatory reaction (Fig. 1) and pTau immunore-
activity (Fig. 4a, compare sham ipsilateral and contralat-
eral staining), we also included treatment-naïve mice
that did not undergo surgery but received ketamine/
xylazine anesthesia. Interestingly, there was not an in-
jury- and side-dependent increase in pTau levels in the
cortex at 3 dpi (Fig. 5a). Yet, mice with both sham sur-
gery and mild LFPI exhibited higher AT8 pTau levels
than naïve mice in a side-independent manner (Fig. 5a).
The levels of pTau were also modulated differentially in
the hippocampus. While hub-placement surgery did not
affect pTau in control mice, they increased pTau in
Ccr2RFP/RFP mice in a “dose”- and side-dependent man-
ner. That is, even surgery itself led to higher pTau on
the ipsilateral side compared to naïve mice, and the
higher “dose”—mild injury—led to an even larger in-
crease in pTau (Fig. 5b).
We quantified pTau levels on the ipsilateral and
contralateral sides separately in order to evaluate the ef-
fects of injury intensity and genotype (Fig. 6). In the ipsi-
lateral cortex, both injury and genotype had a significant
effect on pTau levels (Fig. 6a; two-way ANOVA, p < 0.01
for Injury and p < 0.001 for Genotype). Overall, Ccr2 de-
letion resulted in higher pTau levels after experimental
manipulation of the mice. There was a significant in-
crease in pTau in Ccr2RFP/RFP mice in sham (surgery)
mice compared to naïve mice (two-way ANOVA and
Tukey’s post hoc test, p < 0.01) but not an additional
Fig. 2 Quantification of cavity volume and inflammatory reaction after
TBI. Serial sections were stained for GFP (or Iba1) to visualize microglia
or RFP to visualize infiltrating bone marrow-derived monocytes (BMDM).
Whole slices, lesion cavity, and area of the slices occupied by monocytes
(RFP+ cells) or microglia (increased GFP or Iba1 immunoreactivity) were
manually outlined to calculate their area; all sections were summed up
to calculate volumes. Pathology was quantified as a percentage of the
analyzed brain tissue (4 mm total thickness) that contained the lesion
cavity (a), infiltrating monocytes (b), or increased microglial
staining (c). Statistics: two-way ANOVA and Tukey’s post hoc test.
Comparisons between groups are shown with horizontal lines; vertical
line in figure legend indicates main effect of genotype. *p < 0.05;
**p < 0.01; ***p < 0.001
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increase after mild injury (Fig. 6a). There was a signifi-
cant difference between control and Ccr2RFP/RFP mice
only for the sham surgery groups (Fig. 6a; two-way
ANOVA and Tukey’s post hoc test, p < 0.01). Despite the
change in pTau immunoreactivity in tissue staining
(Fig. 4), there was not a significant difference after injury
in pTau levels in control heterozygous mice (Fig. 6a).
Ccr2RFP/RFP mice were also significantly different from
control mice on the contralateral side of the cortex
(two-way ANOVA, p < 0.05), but there were no signifi-
cant inter-group changes (Fig. 6b).
Consistent with tissue staining (Fig. 4b), we detected
robust changes in pTau levels in the hippocampus on
both the ipsilateral and contralateral sides (Fig. 6c, d),
with both injury and genotype having significant effects
(two-way ANOVA, p < 0.0001 for Genotype for both the
ipsilateral and contralateral sides, p < 0.01 and p < 0.05
for Injury intensity for the ipsilateral and contralateral
sides, respectively). There was a significant difference in
pTau levels after mild injury between control heterozygous
and Ccr2RFP/RFP mice (two-way ANOVA and Tukey’s post
hoc test, p < 0.0001 for both sides). As in the cortex, the
sham surgery induced an increase in pTau in Ccr2RFP/RFP
mice compared to naïve mice that was not subsequently
increased by mild injury (Fig. 6c, d; two-way ANOVA and
Tukey’s post hoc test, p < 0.0001 and p < 0.01 comparing
naïve and mild injured Ccr2RFP/RFP mice on the ipsilateral
and contralateral sides, respectively). Experimental ma-
nipulation or surgery did not significantly affect pTau levels
in control heterozygous mice. Thus, Ccr2 deletion resulted
in increased pTau levels on both the ipsilateral and contra-
lateral sides at 3 days after injury or sham surgery.
Fig. 3 Effects of CCR2 signaling on axonal damage after TBI. Axonal pathology was evaluated at 3 dpi in control heterozygous and Ccr2RFP/RFP
mice by APP staining. a The injury induces APP accumulation in axons of the ipsilateral side to the injury, particularly in the corpus callosum. Ccr2
deletion decreases APP accumulation in axons. Scale bar, 500 μm. b Higher magnification images of the indicated regions (boxes) show that APP
immunoreactivity aligns with axonal tracks in the corpus callosum (CC). Scale bar, 100 μm. c Quantification of axonal pathology as percent area of
the corpus callosum with APP immunoreactivity above threshold. Statistics: two-way ANOVA and Tukey’s post hoc test. Comparisons between
groups are shown with horizontal lines; vertical line in figure legend indicates main effect of genotype. *p < 0.05; **p < 0.01
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Discussion
The inflammation that develops after TBI has the poten-
tial to influence subsequent neuronal pathology [14, 18];
preventing or mitigating aspects of inflammation could
help prevent secondary tissue damage and promote
recovery [17]. Because inflammation is also a feature of
many neurodegenerative conditions, we wanted to
examine if modulating inflammation will also affect
aspects of neurodegeneration such as altered Tau
phosphorylation. We initially examined two models of
altered inflammation: deletion of the chemokine recep-
tor CX3CR1, which primarily affects microglia in the
brain, and deletion of the chemokine receptor CCR2,
which primarily affects bone marrow-derived monocytes
and their extravasation to sites of damage [25, 29]. Only re-
duced monocyte infiltration through Ccr2 deletion reduced
cavity volume and axonal pathology (Figs. 1, 2, and 3),
which led us to examine its effects on tau phosphoryl-
ation. Surprisingly, despite the reduced accumulation of
monocytes at 3 dpi, Ccr2RFP/RFP mice showed increased
pTau levels by both tissue staining and Western blot ana-
lyses (Figs. 4, 5, and 6). Moreover, pTau was translocated
from the axon to the cell body in both the cortex and
hippocampus of Ccr2RFP/RFP mice (Fig. 4). The pathology
Fig. 4 Assessment of tau phosphorylation and localization by tissue staining. Sections from control heterozygous and Ccr2RFP/RFP mice after
surgery (Sham) or mild injury were stained with the AT8 pTau antibody. Images were taken from the cortex near the lesion cavity (a) and the
underlying hippocampus (b) and the corresponding contralateral side. Injury induces increased pTau immunoreactivity as background neuropil
staining in control mice and mislocalization to the cell body in Ccr2RFP/RFP mice. Scale bar, 100 μm. c Insets show pTau staining (AT8, red) in
relation to DAPI-positive nuclei (cyan) for the indicated ipsilateral regions (boxes). Scale bar, 50 μm
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seen in TBI mice here is reminiscent to the neurofibrillary
tangles seen in human tauopathies [31] and in patients
with CTE or after a single TBI event [3, 32, 33].
Modulation of inflammation in Cx3cr1GFP/GFP and
Ccr2RFP/RFP mice
The Cx3cr1GFP/GFP mice that we employed here are com-
monly used to study and visualize microglia in the brain
[29, 34]. Indeed, parenchymal microglia are the predomin-
ant cell type expressing CX3CR1—and GFP—in the brain
as peripheral CX3CR1-positive cells do not cross the in-
tact blood–brain barrier (BBB) in physiological conditions.
However, disruption of the BBB in TBI will allow periph-
eral CX3CR1+ cells to enter the brain. In a dorsal column
crush model of spinal cord injury, CX3CR1+ “patrolling”
monocytes mediate axonal pathology [35]. In our studies,
the great majority of GFP+ cells after TBI had ramified or
bushy morphology (Fig. 1), suggesting that they are micro-
glia. Yet, additional studies are necessary to establish the
ontology of all GFP+ cells after TBI.
Delivery of mild TBI to Cx3cr1GFP/GFP mice did not
significantly affect any of the pathological signs we ex-
amined: microglial activation, recruitment of CCR2+
cells, or lesion cavity, which was in contrast to the clear
effect of Ccr2 deletion (Figs. 1 and 2). Thus, we focused
on CCR2 signaling rather than CX3CR1 signaling in
subsequent analyses. It should be noted that microglial
CX3CR1 signaling has been shown to affect tau
phosphorylation in models of tauopathy. Specifically,
deletion of Cx3cr1 or its ligand Cx3cl1 results in in-
creased tau phosphorylation in mice overexpressing hu-
man tau or the APPPS1 model of AD [11, 36, 37].
Hence, it is plausible that Cx3cr1 deletion might lead to
changes in tau phosphorylation in our mild TBI model,
but this question remains to be addressed.
As with Cx3cr1GFP/GFP mice, Ccr2RFP/RFP mice are sim-
plistically used to study responses by inflammatory
CD45hiLy6Chi monocytes [25, 26]. However, subsets of T
cells, NK cells, and Ly6Clo monocytes express CCR2 or
the RFP reporter in some conditions [26]. Although the
frequency of these other CCR2/RFP+ cells is significantly
lower than the frequency of CCR2+ inflammatory mono-
cytes after TBI [24], we cannot rule out that these cell
types contribute to the pathology. Thus, additional stud-
ies will be necessary to carefully phenotype the different
lymphoid populations that respond to TBI and their role
in TBI outcomes.
Tau phosphorylation after TBI
There is ample evidence that phosphorylated, aggregated
tau is present in the brain of humans that had suffered
from various tauopathies, including CTE, AD, frontotem-
poral dementia, Pick’s disease, and others [31]. In the
context of TBI, pTau has been observed in numerous indi-
viduals who had experienced traumatic events ranging
from repetitive sports-related injuries to isolated head
traumas (for examples, see 32, 3). Yet, there are only a
handful of studies that have examined tau phosphorylation
Fig. 5 Assessment of tau phosphorylation by Western blot. Protein lysates from the cortex (a) or hippocampus (b) of treatment-naïve, sham
(surgery only), or mild injured control or Ccr2RFP/RFP mice were probed for pTau (AT8 antibody, green). GAPDH was used as loading control (red).
Mild injury induced a visible increase on the ipsilateral side of the cortex and hippocampus in Ccr2RFP/RFP mice
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in animal models of TBI. In two different transgenic
tau-overexpressing animals, TBI accelerates tau path-
ology [38, 39]. Using wild type mice, Genis et al. [40]
and Iliff et al. [41] show that TBI can cause tau hyperpho-
sphorylation in the absence of mutated transgene expres-
sion. However, although Genis et al. [40] suggest that tau
phosphorylation is transient, peaking at 4 h, Iliff et al. [41]
demonstrate increased levels of pTau in the brain even at
28 days after injury. Similar to our study, they found that
increased tau phosphorylation is not restricted to the
injured ipsilateral side, but is also detectable to the contra-
lateral side.
Another noteworthy observation from our study is
that the surgery that is required to prepare mice for fluid
percussion injury is sufficient to increase pTau levels
when compared to treatment-naïve mice. Furthermore,
certain types of anesthetics quickly increase the levels of
pTau in the brain [42–44]. In our study, all groups re-
ceived anesthesia, including the treatment-naïve mice.
Thus, the effects of anesthesia alone are not sufficient to
explain the increase of pTau after surgery and injury.
Yet, these findings suggest that tau phosphorylation may
represent an immediate physiological response to brain
disturbances or a biomarker of altered brain homeosta-
sis. It is worth investigating if tau becomes phosphory-
lated in other conditions in which brain function is
impaired, such as stroke, epilepsy, etc. Moreover, al-
though pTau is more prone to aggregation [9], it remains
to be determined if it serves physiological functions that
may be aimed at returning the brain to homeostasis in
the acute time scales.
We were not able to detect a significant increase in
pTau levels after mild injury compared to the surgery
itself. One possibility for this is that the surgery and
Ccr2RFP/RFP genotype synergized to produce a strong
pTau signal, and the deletion of Ccr2 itself sensitizes the
mice to anesthesia- or surgery-mediated effects on pTau.
Then, the delivery of an additional injury with mild in-
tensity may not be sufficient to substantially increase
pTau levels (Fig. 6). However, despite the lack of protein
increase by Western blot, the injury does induce pTau
translocation from the axon to the cell body (Fig. 4). As
a result, surgery (or other brain disturbances) and trau-
matic injury may play distinct, sequential roles to lead to
frank tau pathology.
Ccr2 modulation in TBI
Preventing monocyte accumulation in the brain has be-
come a promising therapeutic approach to treat TBI and
prevent the development of secondary pathologies. Dele-
tion of Ccl2, a ligand for CCR2, Ccr2 itself or antagon-
ism of CCR2 with small molecules have all been shown
to be beneficial after TBI [23, 30, 45–47]. Importantly,
Fig. 6 Quantification of pTau Western blots. The levels of pTau (AT8
antibody) were normalized to the levels of total tau (Tau5 antibody).
a, b Ccr2 genotype significantly affects pTau levels in both the
ipsilateral (a) and contralateral (b) cortex, but pTau levels are
elevated after experimental manipulation (surgery or mild injury)
only on the ipsilateral side. c, d pTau levels in the hippocampus are
increased on both the ipsilateral (c) and contralateral (d) side in
injury- and genotype-dependent manner. As in the cortex, sham
surgery itself elevates pTau levels in the hippocampus. Statistics:
two-way ANOVA and Tukey’s post hoc test. Comparisons between
groups are shown with horizontal lines; vertical line in figure
legend indicates main effect of genotype. *p < 0.05; **p < 0.01;
***p < 0.001; ****p < 0.0001
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interfering with CCR2 signaling results in improved cog-
nitive function for up to 4 weeks after the injury.
Yet, here we show that Ccr2 deletion also leads to in-
creased phosphorylation of tau protein—an event that is
commonly associated with loss of physiological function
and gain of pathological function by tau in a variety of
neurodegenerative diseases [31]. In many of these condi-
tions, tau is found in hyperphosphorylated form in the
cell body of neurons, similar to what we observed here
after TBI in Ccr2RFP/RFP mice. This raises the question
whether interfering with CCR2 signaling might have un-
expected consequences of promoting the development
of pathologies.
There are still important questions that need to be ad-
dressed about the role of CCR2 signaling in tau path-
ology after TBI. First, are the effects of Ccr2 deletion on
tau phosphorylation long lasting or transient? Second,
are other disease-associated epitopes of pTau, such as
AT180, PHF-1, or CP13, affected? The work by Iliff et al.
[41] suggests that tau phosphorylation could persist for
at least 28 days after TBI and affect a variety of pTau
epitopes. Finally, how can the absence of a peripheral
cell type, which is normally not found in the brain, lead
to increased tau phosphorylation? One possible answer
to this last question is that the infiltrating monocytes
modulate the function of resident brain cells such as
neurons, astrocytes, and microglia in the context of TBI;
in the absence of infiltrating monocytes, the resident
cells may release factors that in turn regulate tau phos-
phorylation. Indeed, we did not detect a reduction in the
brain parenchyma occupied by activated microglia in
Ccr2RFP/RFP mice (Figs. 1 and 2). Whether these micro-
glia are functionally and molecularly different from
microglia in control mice after TBI remains to be deter-
mined. Similarly, whether the function of other brain-
resident cell types is affected by the absence of CCR2+
cells in TBI still needs to be examined.
Conclusions
Here we show an unexpected outcome of inhibiting
monocyte infiltration into the brain after TBI in Ccr2RFP/
RFP mice. Although Ccr2 deletion is protective in terms
of lesion volume, axonal pathology, and subsequent be-
havioral outcomes, it leads to increased phosphorylation
and mislocalization of tau protein. The latter has been
associated with neurodegenerative diseases and should
be carefully considered if strategies aimed at CCR2 sig-
naling continue to be pursued for therapeutic purposes
in TBI and other conditions.
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